Analyst consensus rating
iRadimed Analyst Rating: none
IRMD is rated none by 2 analysts with a $118.00 target. As of 2026-08-23.
Direct answer
iRadimed's consensus rating is none.
2 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $118.00.
Forecast evidence checked August 23, 2026.
Get free iRadimed email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $87.85
- Average price target
- $118.00
- High price target
- $120.00
- Low price target
- $116.00
- Low target gap
- +32%
- Target upside
- +34.3%
- High target gap
- +36.6%
- Target range width
- 4.6%
- Consensus rating
- none
- Analysts
- 2
- Evidence date
- August 23, 2026
- Valid through
- August 30, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for iRadimed?
iRadimed has a verified none consensus. The same dataset has an average price target of $118.00.
How far are iRadimed's low and high targets from the recorded price?
The low target implies +32%, while the high target implies +36.6%.
How many analysts are included in iRadimed's consensus?
The verified consensus includes 2 analysts.
How is iRadimed's target upside or downside calculated?
The average target of $118.00 is divided by the recorded price of $87.85, then one is subtracted to produce +34.3%. This does not guarantee a future return.
When was iRadimed's analyst forecast verified?
The data was verified on 2026-08-23. The dataset is valid through 2026-08-30.